Oscar Health, Inc. (OSCR) Cash Flow Statement
Where OSCR’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $1.09B +11.9% vs 2024
- Capital expenditures
- $36.4M 0.3% of revenue
- Free cash flow
- $1.06B 9.0% margin
- Returned to shareholders
- —
- Change in cash
- $1.25B cash at year-end $2.80B
Drawn to scale: where the cash came from and how it was used. Hover for values.
OSCR operating cash flow, capex and free cash flow
OSCR cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$165.4M2019 | $1.09B2025 | — | |
| Capital expenditures | $26.0M2019 | $36.4M2025 | +5.8%/yr | |
| Free cash flow | −$191.4M2019 | $1.06B2025 | — | |
| Free cash flow margin | −34.6%2019 | 9.0%2025 | +43.6 pts | |
| Stock-based compensation | $33.6M2019 | $87.7M2025 | +17.4%/yr | |
| Share buybacks (net) | $3.0M2019 | $02022 | −100.0% | |
| Capex / revenue | 4.7%2019 | 0.3%2025 | −4.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
OSCR cash flow by activity
OSCR net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
OSCR cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$442.9M | $26.1M | −$270.6M | −$609.6M | −$571.4M | −$406.8M | −$261.2M |
| Depreciation & amortization | $28.9M | $32.1M | $30.7M | $15.3M | $14.6M | $11.3M | $6.9M |
| Stock-based compensation | $87.7M | $109.8M | $159.7M | $112.3M | $86.3M | $35.9M | $33.6M |
| Change in working capital | $1.46B | $838.9M | −$192.1M | $855.0M | $247.7M | $575.7M | $62.2M |
| Other non-cash items | −$37.8M | −$28.8M | $144,000 | $7.3M | $41.1M | $6.7M | −$6.9M |
| Cash from operating activities | $1.09B | $978.2M | −$272.2M | $380.3M | −$181.7M | $222.7M | −$165.4M |
| Investing activities | |||||||
| Capital expenditures | −$36.4M | −$27.9M | −$25.6M | −$29.0M | −$25.9M | −$14.0M | −$26.0M |
| Investments (net) | −$209.0M | −$1.39B | −$302.0M | −$226.5M | −$755.3M | −$329.4M | $183.6M |
| Acquisitions & other investing | $4.3M | $27.9M | $904.7M | $29.0M | $6.7M | −$1.2M | −$7.1M |
| Cash from investing activities | −$241.1M | −$1.39B | $577.2M | −$226.5M | −$774.5M | −$344.7M | $150.5M |
| Financing activities | |||||||
| Share repurchases & issuance (net) | — | — | — | $3.1M | $1.40B | $0 | −$3.0M |
| Net borrowing (repayment) | $410.0M | $0 | $0 | $298.0M | −$153.2M | $147.0M | $147.0M |
| Shares issued | $0 | $0 | $0 | $0 | $1.35B | $375.7M | $0 |
| Other financing | −$10.8M | $68.4M | $6.4M | $0 | −$1.36B | $89.0M | −$146.1M |
| Cash from financing activities | $399.2M | $68.4M | $6.4M | $301.1M | $1.24B | $611.7M | −$2.1M |
| Summary | |||||||
| Net change in cash | $1.25B | −$340.9M | $311.5M | $454.9M | $282.5M | $489.7M | −$17.0M |
| Cash at end of period | $2.80B | $1.55B | $1.89B | $1.58B | $1.13B | $843.1M | $353.4M |
| Free cash flow | $1.06B | $950.3M | −$297.7M | $351.3M | −$207.6M | $208.7M | −$191.4M |
| Free cash flow margin | 9.0% | 10.4% | −5.1% | 8.5% | −10.8% | 35.4% | −34.6% |
| Capex / revenue | 0.3% | 0.3% | 0.4% | 0.7% | 1.3% | 2.4% | 4.7% |
| Operating cash flow / net income | — | 37.45 | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $361.8M | $679.0M | −$352.4M | −$137.5M | −$228.5M | $275.5M | −$153.3M | −$54.2M | $56.3M | $177.5M | −$149.8M | −$65.7M |
| Depreciation & amortization | $6.0M | $7.0M | $7.9M | $7.3M | $7.0M | $6.7M | $9.2M | $7.5M | $7.6M | $7.8M | $7.7M | $9.2M |
| Stock-based compensation | $20.7M | $16.0M | $18.1M | $20.5M | $24.1M | $25.0M | $25.9M | $29.3M | $28.7M | $25.9M | $26.1M | $28.8M |
| Change in working capital | −$1.97B | $1.93B | $988.4M | −$846.5M | $729.6M | $587.5M | $473.8M | −$840.6M | $410.4M | $430.2M | $390.6M | −$1.12B |
| Other non-cash items | $3.63B | −$12.3M | $10.0M | −$8.4M | −$23.1M | −$16.2M | −$8.8M | $357.8M | −$5.9M | −$7.1M | $22.3M | −$5.0M |
| Cash from operating activities | $2.05B | $2.62B | $671.9M | −$964.7M | $509.1M | $878.5M | $346.8M | −$500.1M | $497.2M | $634.4M | $296.9M | −$1.15B |
| Investing activities | ||||||||||||
| Capital expenditures | −$11.8M | −$8.8M | −$9.1M | −$9.0M | −$9.3M | −$9.0M | −$6.8M | −$7.6M | −$7.6M | −$6.0M | −$6.1M | −$6.5M |
| Investments (net) | −$2.82B | −$580.6M | −$40.7M | $150.1M | −$168.2M | −$174.2M | −$31.4M | −$577.8M | −$477.6M | −$300.6M | $172.5M | $225.3M |
| Acquisitions & other investing | $1.5M | −$860,000 | $1.1M | $9.0M | $9.3M | $9.0M | $6.8M | $7.6M | $7.6M | $6.0M | $6.1M | $6.5M |
| Cash from investing activities | −$2.83B | −$590.3M | −$48.7M | $150.1M | −$168.2M | −$174.2M | −$31.4M | −$577.8M | −$477.6M | −$300.6M | $172.5M | $225.3M |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | $0 | — | — | — | — | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $12.2M | −$3.6M | $8.2M | $364.0M | $22.1M | $4.9M | $3.8M | $18.6M | $18.7M | $27.3M | $1.1M | $2.3M |
| Cash from financing activities | $12.2M | −$3.6M | $8.2M | $364.0M | $22.1M | $4.9M | $3.8M | $18.6M | $18.7M | $27.3M | $1.1M | $2.3M |
| Summary | ||||||||||||
| Net change in cash | −$775.2M | $2.03B | $625.3M | −$450.1M | $363.0M | $709.2M | $319.2M | −$1.06B | $38.2M | $361.1M | $470.4M | −$921.6M |
| Cash at end of period | $4.05B | $4.83B | $2.77B | $2.15B | $2.62B | $2.26B | $1.55B | $1.23B | $2.29B | $2.25B | $1.89B | $1.42B |
| Free cash flow | $2.04B | $2.61B | $662.8M | −$973.7M | $499.8M | $869.5M | $340.0M | −$507.7M | $489.6M | $628.4M | $290.8M | −$1.16B |
| Free cash flow margin | 41.7% | 56.2% | 23.6% | −32.6% | 17.5% | 28.5% | 14.2% | −20.9% | 22.1% | 29.3% | 20.3% | −80.3% |
| Capex / revenue | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% |
| Operating cash flow / net income | 5.66 | 3.86 | — | — | — | 3.19 | — | — | 8.83 | 3.57 | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
OSCR cash generation
In fiscal 2025 (ended December 31, 2025), Oscar Health generated $1.1 billion of cash from operations (up 11.9%) and spent $36.4 million on capital expenditures, leaving free cash flow of $1.1 billion, 9.0% of revenue. Cash and equivalents rose by $1.3 billion over the year.
Related: OSCR income statement, OSCR balance sheet. See the OSCR stock overview for the latest quote and news.
OSCR cash flow FAQ
What is Oscar Health's free cash flow?
Oscar Health's free cash flow was $1.1 billion in fiscal 2025: $1.1 billion of operating cash flow minus $36.4 million of capital expenditures It was $950.3 million a year earlier..
How much cash does Oscar Health generate from operations?
Oscar Health generated $1.1 billion of cash from operating activities in fiscal 2025.
How much does Oscar Health spend on capital expenditures?
Oscar Health spent $36.4 million on capital expenditures in fiscal 2025, 0.3% of revenue, compared with $27.9 million the year before.